

Texas Department of Insurance

Division of Workers' Compensation - Medical Fee Dispute Resolution (MS-48) 7551 Metro Center Drive, Suite 100, Austin, Texas 78744-1645 (512) 804-4000 | F: (512) 804-4811 | (800) 252-7031 | TDI.texas.gov | @TexasTDI

MEDICAL FEE DISPUTE RESOLUTION FINDINGS AND DECISION

GENERAL INFORMATION

<u>Requestor Name</u> Memorial Compounding Pharmacy Respondent Name

Safety National Casualty Corporation

MFDR Tracking Number

M4-19-0738-01

<u>Carrier's Austin Representative</u> Box Number 19

MFDR Date Received October 11, 2018

REQUESTOR'S POSITION SUMMARY

<u>Requestor's Position Summary</u>: "After reviewing the explanation of benefits it indicates that carrier paid **\$0.00** and not the full amount of **\$160.86**."

Amount in Dispute: \$160.86

RESPONDENT'S POSITION SUMMARY

<u>Respondent's Position Summary</u>: Submitted documentation does not include a position statement from the respondent. Accordingly, this decision is based on the information available at the time of adjudication.

SUMMARY OF FINDINGS

Dates of Service	Disputed Services	Amount In Dispute	Amount Due
February 28, 2018	Cyclobenzaprine 5 mg Tablets	\$160.86	\$133.20

FINDINGS AND DECISION

This medical fee dispute is decided pursuant to Texas Labor Code §413.031 and applicable rules of the Texas Department of Insurance, Division of Workers' Compensation.

Background

- 1. 28 Texas Administrative Code §133.307 sets out the procedures for resolving medical fee disputes.
- 2. 28 Texas Administrative Code §134.503 sets out the fee guidelines for pharmaceutical services.
- 3. 28 Texas Administrative Code §134.530 sets out the closed formulary requirements for claims not subject to certified networks.
- 4. The insurance carrier denied payment for the disputed drugs based on preauthorization.

<u>Issues</u>

- 1. Did Safety National Casualty Corporation (Safety National) respond to the medical fee dispute?
- 2. Is Safety National's denial of payment based on preauthorization supported?
- 3. Is the requestor entitled to reimbursement for the drug in question?

Findings

 The insurance carrier's Austin representative acknowledged receipt of the copy of this medical fee dispute on October 18, 2018. The insurance carrier's response is considered timely if it is submitted within 14 calendar days after the date the insurance carrier's representative received the copy of the dispute. If a response is not received within 14 calendar days of the dispute notification, then the decision may be based on the available information.¹

No response has been received on behalf of Safety National to date. For that reason, the decision will be based on the information available.

- 2. Memorial is seeking reimbursement for Cyclobenzaprine 5 mg tablets dispensed on February 28, 2018. The insurance carrier denied the disputed drugs based on preauthorization. Preauthorization is only required for:
 - drugs identified with a status of "N" in the current edition of the ODG Appendix A²;
 - any compound that contains a drug identified with a status of "N" in the current edition of the ODG Appendix A; and
 - any investigational or experimental drug.³

The division finds that the drug in question is not identified with a status of "N" in the applicable edition of the ODG, *Appendix A*. Therefore, this drug does not require preauthorization per 28 TAC §134.530(b)(2)(A).

The submitted documentation does not support that the drug in question constitutes a compound drug. Therefore, these drugs do not require preauthorization per 28 TAC §134.530(b)(2)(B).

The submitted documentation does not support that the disputed drug is experimental or investigational. Therefore, this drug does not require preauthorization per 28 TAC §134.530(b)(2)(C).

The division concludes that Safety National's denial of payment of the disputed drug based on preauthorization is not supported.

3. Because the insurance carrier failed to support its denial of payment, Memorial is entitled to reimbursement for the drug in question.

The reimbursement considered in this dispute is calculated as follows⁴:

• Cyclobenzaprine 5 mg tablets: (1.7226 x 60 x 1.25) + \$4.00 = \$133.20

The total reimbursement is therefore \$133.20. This amount is recommended.

Conclusion

For the reasons stated above, the Division finds that the requestor has established that additional reimbursement is due. As a result, the amount ordered is \$133.20.

¹ 28 Texas Administrative Code §133.307(d)(1)

² ODG Treatment in Workers' Comp (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary

³ 28 Texas Administrative Code §134.540(b)

⁴ 28 Texas Administrative Code §134.503(c)

ORDER

Based on the submitted information, pursuant to Texas Labor Code Section 413.031 and 413.019 (if applicable), the division has determined the requestor is entitled to additional reimbursement for the disputed services. The division hereby ORDERS the respondent to remit to the requestor \$133.20, plus applicable accrued interest per 28 Texas Administrative Code §134.130, due within 30 days of receipt of this order.

Authorized Signature

Signature

Laurie Garnes Medical Fee Dispute Resolution Officer March 27, 2019 Date

YOUR RIGHT TO APPEAL

Either party to this medical fee dispute has a right to seek review of this decision in accordance with Rule §133.307, effective May 31, 2012, *37 Texas Register 3833*, applicable to disputes filed on or after June 1, 2012.

A party seeking review must submit a **Request to Schedule a Benefit Review Conference to Appeal a Medical Fee Dispute Decision** (form **DWC045M**) in accordance with the instructions on the form. The request must be received by the division within **twenty** days of your receipt of this decision. The request may be faxed, mailed or personally delivered to the division using the contact information listed on the form or to the field office handling the claim.

The party seeking review of the MFDR decision shall deliver a copy of the request to all other parties involved in the dispute at the same time the request is filed. **Please include a copy of the** *Medical Fee Dispute Resolution Findings and Decision* together with any other required information specified in 28 Texas Administrative Code §141.1(d).

Si prefiere hablar con una persona en español acerca de ésta correspondencia, favor de llamar a 512-804-4812.